Vor Bio (VOR) said Wednesday its collaborator RemeGen achieved the primary endpoint in a phase 3 clinical study evaluating telitacicept in adults with IgA nephropathy in China.

The study, which enrolled 318 adult patients, demonstrated a 55% reduction in urine protein-to-creatinine ratio after 39 weeks, meeting the primary endpoint, the company said.

Telitacicept showed a favorable safety profile in the trial, the biotechnology company said.

RemeGen plans to submit a biologics license application for IgAN to China's National Medical Products Administration, Vor Bio said.

Shares of the company were up 1% in recent Wednesday premarket activity.